Cargando…

PPARα: A potential therapeutic target of cholestasis

The accumulation of bile acids in the liver leads to the development of cholestasis and hepatocyte injury. Nuclear receptors control the synthesis and transport of bile acids in the liver. Among them, the farnesoid X receptor (FXR) is the most common receptor studied in treating cholestasis. The act...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiaoyin, Zhang, Tong, Han, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342652/
https://www.ncbi.nlm.nih.gov/pubmed/35924060
http://dx.doi.org/10.3389/fphar.2022.916866
_version_ 1784760869325897728
author Ye, Xiaoyin
Zhang, Tong
Han, Han
author_facet Ye, Xiaoyin
Zhang, Tong
Han, Han
author_sort Ye, Xiaoyin
collection PubMed
description The accumulation of bile acids in the liver leads to the development of cholestasis and hepatocyte injury. Nuclear receptors control the synthesis and transport of bile acids in the liver. Among them, the farnesoid X receptor (FXR) is the most common receptor studied in treating cholestasis. The activation of this receptor can reduce the amount of bile acid synthesis and decrease the bile acid content in the liver, alleviating cholestasis. Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) have a FXR excitatory effect, but the unresponsiveness of some patients and the side effect of pruritus seriously affect the results of UDCA or OCA treatment. The activator of peroxisome proliferator-activated receptor alpha (PPARα) has emerged as a new target for controlling the synthesis and transport of bile acids during cholestasis. Moreover, the anti-inflammatory effect of PPARα can effectively reduce cholestatic liver injury, thereby improving patients’ physiological status. Here, we will focus on the function of PPARα and its involvement in the regulation of bile acid transport and metabolism. In addition, the anti-inflammatory effects of PPARα will be discussed in some detail. Finally, we will discuss the application of PPARα agonists for cholestatic liver disorders.
format Online
Article
Text
id pubmed-9342652
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93426522022-08-02 PPARα: A potential therapeutic target of cholestasis Ye, Xiaoyin Zhang, Tong Han, Han Front Pharmacol Pharmacology The accumulation of bile acids in the liver leads to the development of cholestasis and hepatocyte injury. Nuclear receptors control the synthesis and transport of bile acids in the liver. Among them, the farnesoid X receptor (FXR) is the most common receptor studied in treating cholestasis. The activation of this receptor can reduce the amount of bile acid synthesis and decrease the bile acid content in the liver, alleviating cholestasis. Ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) have a FXR excitatory effect, but the unresponsiveness of some patients and the side effect of pruritus seriously affect the results of UDCA or OCA treatment. The activator of peroxisome proliferator-activated receptor alpha (PPARα) has emerged as a new target for controlling the synthesis and transport of bile acids during cholestasis. Moreover, the anti-inflammatory effect of PPARα can effectively reduce cholestatic liver injury, thereby improving patients’ physiological status. Here, we will focus on the function of PPARα and its involvement in the regulation of bile acid transport and metabolism. In addition, the anti-inflammatory effects of PPARα will be discussed in some detail. Finally, we will discuss the application of PPARα agonists for cholestatic liver disorders. Frontiers Media S.A. 2022-07-18 /pmc/articles/PMC9342652/ /pubmed/35924060 http://dx.doi.org/10.3389/fphar.2022.916866 Text en Copyright © 2022 Ye, Zhang and Han. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ye, Xiaoyin
Zhang, Tong
Han, Han
PPARα: A potential therapeutic target of cholestasis
title PPARα: A potential therapeutic target of cholestasis
title_full PPARα: A potential therapeutic target of cholestasis
title_fullStr PPARα: A potential therapeutic target of cholestasis
title_full_unstemmed PPARα: A potential therapeutic target of cholestasis
title_short PPARα: A potential therapeutic target of cholestasis
title_sort pparα: a potential therapeutic target of cholestasis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342652/
https://www.ncbi.nlm.nih.gov/pubmed/35924060
http://dx.doi.org/10.3389/fphar.2022.916866
work_keys_str_mv AT yexiaoyin pparaapotentialtherapeutictargetofcholestasis
AT zhangtong pparaapotentialtherapeutictargetofcholestasis
AT hanhan pparaapotentialtherapeutictargetofcholestasis